CELLECT is revolutionizing women’s health diagnostics with a non-invasive, accessible, and cost-effective solution. Using patented nanotechnology, CELLECT’s innovative collection device is embedded in menstrual products, capturing and stabilizing cervical cells and DNA directly from menstrual blood. This groundbreaking approach eliminates the need for invasive procedures like Pap smears, overcoming barriers of accessibility, affordability, and cultural stigma that hinder traditional screening methods.

Targeting HPV and cervical cancer diagnostics as a starting point, CELLECT’s technology is designed to integrate seamlessly with existing gold-standard laboratory testing. Beyond cervical cancer, CELLECT’s platform has the potential to expand into diagnostics for other reproductive health conditions, such as endometriosis and STIs, as well as leveraging vaginal fluids for further R&D applications.

Nanosolutions for women’s biggest health problems.

Tired of invasive tests and waiting for appointments? CELLECT is pioneering the use of nanotechnology-powered menstrual products to non-invasively collect and preserve DNA for the diagnosis of HPV, cervical cancer, STDs, and other reproductive & gynaecological conditions.

CELLECT provides a passive alternative to Pap smears by using menstrual blood collection through menstrual products, eliminating the need for invasive procedures like swabs or speculums. This makes our solution especially valuable for women who may face cultural or religious barriers that discourage or prevent them from undergoing traditional cervical cancer screenings. Unlike swabs, CELLECT’s technology doesn’t require anything to be inserted, offering a more comfortable and discreet option that can be done in the privacy of one’s own home.

For women who do not menstruate, CELLECT is actively exploring the use of other vaginal fluids, such as discharges, as an alternative sample. Our proprietary technology is designed to work with very small fluid volumes— as little as 15 mm³ — allowing us to achieve the same diagnostic goals. This ensures that our solution remains inclusive and adaptable, providing a non-invasive, accurate method for women across different health stages.

CELLECT collects DNA from menstrual blood using its proprietary nanomaterial, which isolates and retains cervical and endothelial cells. This DNA can then be analyzed using established diagnostic tests, such as HPV hybridization assays. The lab processing techniques CELLECT uses are the same as those applied in standard HPV tests, allowing for the differentiation between high-risk and low-risk strains.

We are on a mission to improve the accessibility of life-saving screening for women globally.